Purpose: Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death in the United States, and its incidence is on the rise. Advanced disease is nearly uniformly lethal, emphasizing the need to identify PDA at its earliest stages. To discover early biomarkers of PDA, we evaluated the circulating proteome in murine preinvasive and invasive plasma samples and human prediagnostic and diagnostic samples.
Introduction
Survival rates for many cancers, including breast, colon, and prostate, have improved significantly in the past two decades, but the prognosis for pancreatic ductal adenocarcinoma (PDA), or pancreas cancer, has remained dismal. Five-year survival rates remained unchanged at approximately 6% from 2002 to 2008 (1) , which is of additional concern, given the 1.2% annual increase in incidence from 1999 to 2010 (SEER incidence, seer. cancer.gov/faststats/selections). Surgical resection remains the only curative option, but the majority (>80%) of patients present with unresectable disease at diagnosis, highlighting the need for improved early detection strategies (2) . Patients diagnosed with localized, resectable disease have 5-year survival rates that improve to a modest 20% (3) , with a median survival of approximately 20 months (4). These outcomes reflect the micrometastatic capability of PDA early in disease progression and the challenges in detecting occult disseminated disease.
The retroperitoneal location of the pancreas together with its cargo of digestive enzymes impede safe and efficient biopsy of the organ, making a diagnostic test on readily accessible biologic fluids an attractive alternative. The only FDA-approved bloodbased marker for pancreatic cancer is CA19-9, but with sensitivities and specificities ranging from 60% to 70% and 70% to 85%, respectively (5), it is not recommended for screening, as a diagnostic, or to determine operability. CA19-9 is instead typically used to assess response to treatment and/or disease recurrence in people that express elevated levels at diagnosis (6, 7) . Numerous studies have focused on identifying serum, tissue, ascites, and cyst fluid markers for early detection, although the majority of samples in these studies were obtained at diagnosis, at which point most patients are incurable. For markers to be clinically meaningful for disease detection of PDA, they should ideally be present and measurable at subclinical stages. Biologic fluids collected in large, prospective, longitudinal cohort studies provide a unique resource for specimens drawn before clinical diagnosis of disease. Such specimens are especially invaluable for PDA, which has a relatively low incidence and is frequently asymptomatic at early stages.
In the present study, we used our high-density antibody microarray platform (8) (9) (10) customized for pancreas cancer (11) , to interrogate: (i) plasma drawn at distinct time points from a highly faithful genetically engineered mouse model of pancreas cancer (12) ; (ii) prediagnostic plasma from women who later succumbed to PDA; and (iii) diagnostic plasma from patients. By further focusing on identified plasma membrane and secreted proteins, we identified two markers that overlapped between mouse and prediagnostic human datasets, and that have individually been previously implicated in PDA; a third novel marker, ESR1, was identified by multiple distinct antibodies in prediagnostic human plasma samples. In a subsequent set of array experiments on a separate cohort of 24 diagnostic PDA samples, all three markers were again upregulated in PDA compared with an equal number of controls, collectively providing preliminary confirmation across multiple sample sets. The implications of these findings and the potential applicability of this 3-marker panel to early diagnosis of pancreas cancer are further discussed.
Materials and Methods
Patient samples Prediagnostic samples. Eighty-seven prediagnostic PDA and 87 matched control plasma samples collected in EDTA were obtained from the Women's Health Initiative's (WHI) observational study. Controls were matched 1:1 to PDA cases based on the following criteria: age at screening; year of WHI enrollment; alcohol consumption at baseline; race/ethnicity; smoking status (never, past, and current); diabetes history (yes or no); prior hormone replacement therapy (none, estrogen only, and estrogen and progesterone); blood draw visit (baseline only, baseline and year 3, and year 3 only); and duration of follow-up. A reference pool of EDTA-collected plasma was created by pooling plasma drawn from a group of 7 female volunteers from the Fred Hutchinson Cancer Research Center, ages 27 to 45 years. All samples were deidentified and the study was approved by the FHCRC Institutional Review Board.
Diagnostic samples. Twenty-four diagnostic EDTA-collected plasma samples were provided by the Center for Accelerated Translation in Pancreas Cancer (CATPAC) at the Seattle Cancer Care Alliance (Seattle, WA). Twenty-four unmatched control (not diagnosed with any cancer) plasma samples were collected and processed at the same clinic using the same methods. All patient information provided was done so in accordance with the Institutional Review Board at the Fred Hutchinson Cancer Research Center.
Mouse plasma collection. Murine plasma samples were acquired from 17 Kras LSL-G12D/þ ;Trp53
;Pdx-1-Cre or p48 Cre/þ (KPC) and age-matched KP and Cre control mice on a C57BL/6/SV129 mixed background following brief anesthesia with isoflurane (12) . Either Pdx-1 or p48 promoters were used to drive Cre expression and target pancreas-specific expression of the point mutant alleles (13) . Blood (up to 200 mL) was collected every 2 weeks from KPC and age-matched control mice into tubes containing 10 mL 0.5 mol/L EDTA. Samples were centrifuged (4,000 Â g Â 10 minutes), the supernatant collected and recentrifuged (16,000 Â g Â 10 minutes), and aliquots stored at À80 C until use in array experiments.
Mouse tissue collection and induction of chronic pancreatitis. Tissue from the head of the pancreas of 2-month-old (n ¼ 5), 4-monthold (n ¼ 5) and end-stage disease KPC (n ¼ 8), and age-matched KP and Cre control animals (n ¼ 4 each/time point) was collected at necropsy and flash frozen until use in antibody microarray experiments. Tissues were similarly harvested from a cohort of six 2-month-old wild-type (WT) mice injected i.p. with 100 mL cerulein (50 mg/mL) for 23 consecutive days to induce chronic pancreatitis and necropsies were performed within 6 hours of the final injection. All mouse husbandry and procedures were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee at the Fred Hutchinson Cancer Research Center.
Sample preparation for antibody microarray analysis Plasma samples were depleted of IgG and serum albumin using the Proteoprep Immunoaffinity Albumin and IgG Depletion Kit per the manufacturer's instructions (Sigma-Aldrich). Protein lysates from depleted case and control plasma samples (250 mg total protein) and murine tissue samples (200 mg total protein) were labeled with N-hyroxysuccinimide (NHS)-Cy5 (GE Health Biosciences); reference pools of plasma and tissue lysates collected from WT mice were labeled with NHS-Cy3. Murine tissues were incubated in lysis buffer (10:1 volume-to-weight) containing 1% NP-40, 0.25% deoxycholate, 0.25% octyl-b-d-glucopyranoside, and 0.25% amidosulfobetaine-14 supplemented with phosphatase inhibitors, Roche protease inhibitor cocktail (Roche USA), and 1 mmol/L phenylmethylsulfonylfluoride.
Antibody microarray interrogation
Antibody microarrays were printed and incubated with labeled plasma and tissue samples on Nexterion H slides (Schott) essentially as previously described (9) . Briefly, antibodies were printed in triplicate in a 16 Â 16 block format with 48 blocks per array for a total of 3 Â 4,096 unique features. Antibodies were printed at a final concentration of 175 to 350 mg/mL. Following a "casecontrol versus reference" procedure, individual Cy5-labeled case and control samples were pooled with an equal amount of Cy3-labeled reference to remove dye bias from the analyses. Labeled lysates were incubated on arrays for 1.5 hours, washed serially to remove excess dye, and the arrays scanned and analyzed using an Axon Genepix 4200A scanner (Molecular Devices, LLC).
Translational Relevance
Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death in the United States. Surgical resection when feasible confers a survival advantage, but PDA is otherwise nearly uniformly lethal. To discover potential biomarkers for improved early diagnosis of PDA, we created a customized, high-dimensional antibody microarray platform and interrogated plasma samples from cohorts of a highly faithful mouse model of PDA representing preinvasive and early invasive stages of disease, respectively. We also tested prediagnostic human plasma samples and validated the results in diagnostic samples from patients with PDA. Collectively, these analyses uncovered biologically and potentially clinically relevant markers detectable up to 4 years before death from PDA. These results establish the potential of circulating biomarkers to detect disease before the emergence of clinical symptoms and to critically inform clinical decision making.
Array analyses and statistics
For each antibody, the difference in case-control signal (red channel) compared with reference (green channel), known as the M value, was calculated as log 2 (R c /G c ), where R c is red corrected, and G c is green corrected (using the normexp background correction method developed by Smyth and Speed, ref. 14) . Saturated array spots were flagged and triplicate antibodies with coefficients of variation >10% were removed before array normalization. Following localized background correction, print tip loess intraarray normalization was performed. Interarray green channel quantile adjustment was applied to normalize the reference (green) signal. The median intensity of triplicate spots for each antibody feature was calculated and control signal was subsequently standardized to have a mean signal of zero with an SD of 1. For the WHI prediagnostic plasma dataset using the 87 cases and 87 matched controls, linear regression [which considers covariate effects such as incubation day, print day and body mass index (BMI)] was used. Paired t tests were conducted for the adjusted measures. For the diagnostic plasma dataset, linear regression was fitted factoring in the incubation day; for the mouse plasma and tissue data, we used logistic regression after removing the incubation day effect. Candidate protein markers were then ranked on the basis of their P values and effect size/ORs (WHI and CATPAC) or logistic regression OR (mouse plasma and tissue). A positive OR means that the candidate protein is greater in cancer than controls; a negative value means the converse. All normalization procedures and analyses were conducted using R statistical computing software program. Markers were combined as previously described (15) . CA19-9 was analyzed using a Luminex bead-based immunoassay as previously described (16) . The statistical analyses presented in Fig. 2 used a paired two-tailed t test for the WHI samples and unpaired two-tailed t tests for the murine and CATPAC diagnostic sample sets, respectively, and were computed using GraphPad Prism 5.0. ROC curves and AUCs were calculated as previously described (17) .
Immunohistochemistry
Sections (4 mm) of formalin-fixed paraffin-embedded tissues were deparaffinized with xylene and rehydrated sequentially. Antigen retrieval was performed in a pressure cooker in Trilogy pH 8.0 Buffer (Cell Marque) and subsequent incubations performed on a Dako Autostainer Plus (Agilent Technologies). Slides were treated with 3% hydrogen peroxide, blocked with TCT Buffer (0.05 mol/L Tris, 0.15 mol/L NaCl, 0.25% Casein, 0.1% Tween 20, and pH 7.6) and incubated with anti-TNC antibody (1:75; Novus Biologicals) or a matched concentration of rabbit IgG. Poly-HRP anti-Rabbit IgG Polymer (Leica Microsystems) was then applied followed by DAB þ substrate-chromagen (Agilent Technologies).
Slides were counterstained with hematoxylin (Agilent). Serial sections were stained with hematoxylin and eosin (H&E) for histologic analyses. All images were captured with a Nikon DSVi1 brightfield camera using NIS Elements 3.2 Basic Research Image software (Nikon Instruments Inc.).
Results
Antibody microarray interrogation of murine preinvasive and invasive plasma To discover and develop potential diagnostic biomarkers of early-stage pancreas cancer, we began with plasma collected serially from the highly faithful KPC mouse model of PDA (12) . These mice develop invasive PDA with high penetrance and recapitulate the clinical, histologic, and molecular characteristics of the cognate human disease. As such, they have been used extensively in preclinical treatment studies (18) (19) (20) . Plasma samples from two specific time points, namely 6 to 8 weeks, representing preinvasive disease (time point #1, or TP1); and midway through the lifespan of each individual KPC mouse (time point #2, or TP2), representing early invasive adenocarcinoma, were compared with controls on an antibody array platform containing 4,096 unique features (8) (9) (10) . No palpable masses or clinical symptoms were evident in the cohorts at either of the two time points. The array platform was tailored for interrogation of pancreas cancer tissue and plasma samples by including approximately 130 antibodies based on their relevance to PDA. These included antibodies against proteins identified as markers of PDA in a published compendium (21) , with further enrichment for putative early detection markers of PDA, that is, markers identified in high-grade precursor pancreatic intraepithelial neoplasia 3 (PanIN-3) lesions. Logistic regression analyses identified 54 proteins at TP1 (21 proteins that were upregulated and 33 downregulated in KPC plasma vs. controls) and 25 proteins at TP2 (12 up, 13 down; Fig. 1A and B; Supplementary Table S1) that Figure 1 . Antibody microarray interrogation of murine preinvasive (A) and invasive (B) pancreas cancer plasma and human prediagnostic (WHI) plasma samples (C and D). Plasma samples were drawn up to 4 years before death from PDA in patients diagnosed across all stages of disease (C). Statistical significance was computed using an unpaired two-tailed t test in GraphPad Prism 5.0; Ã , P < 0.05 for stage IA and IIA versus IV; ÃÃ , P < 0.01 for stage IB and IIB versus IV; and ÃÃÃ , P < 0.001 for stage III versus IV. Samples from patients where stage at diagnosis could not be determined were not included in these comparisons. Volcano plots depict the P values and accompanying OR for each antibody feature on the array platform. Candidate markers with P < 0.05 are found above the line (estimated), and the number of significant candidates-both upregulated and downregulated in disease versus control plasma-are indicated in the top left corner for each dataset.
differentiated KPC from control plasma with statistical significance (P < 0.05). (We note that none are significant if adjusted for multiple-comparison testing, given the very high dimensionality of the array.) Among the upregulated markers were the plasma membrane proteins IL12RB2, AQP2, PCDH15, ICAM5, OPN3, CD27 (TP1), and RAB7L1, EZR, ERBB2, CCR2, and CSF3R (TP2); and the extracellular or secreted markers TNC, HBA1, PTHLH (TP1), and B2M and SERPING1 (TP2).
Antibody microarray interrogation of prediagnostic human plasma samples
To identify putative protein markers that could be used to detect PDA in asymptomatic individuals, we interrogated prediagnostic plasma samples drawn from a large cohort of subjects who succumbed to PDA within 4 years after the blood draw and matched controls (see Materials and Methods for matching criteria and Table 1 for sample characteristics). The time from blood draw to diagnosis for this sample set ranged from 33 days to just under 4 years, and the time from diagnosis to death ranged from 0 to just under 700 days. The samples were derived from patients diagnosed at different stages of disease, and the population reflected the expected heterogeneity of PDA based on the range in time to death following diagnosis (Fig. 1C) . A paired t test identified a total of 88 candidate markers differentiating prediagnostic plasma samples from controls with statistical significance (P < 0.05, although none are significant when adjusting for multiple comparison testing). Twenty-three of these markers were upregulated and 65 were downregulated (Fig. 1D) . The complete list of upregulated candidate early detection markers is provided in Table 2 (downregulated proteins are listed in Supplementary  Table S2 ). The median interarray variation across 27 arrays incubated with replicate samples in a blinded manner was 0.043 (range, 0.0009-0.29), showing strong reproducibility across individual arrays.
As the goal was to identify early disease plasma markers that could be used in a noninvasive blood test, we focused our attention on the upregulated proteins. We cross-referenced our list to that at pancreaticcancerdatabase.org and the compendium developed by Harsha and colleagues (21) , and found that 15 of these 23 putative markers have been previously associated with pancreatic neoplasms, confirming the fidelity of the array platform and methodology. Eight of these 23 markers have also been Cross-species identification of elevated TNC and ERBB2 in KPC pancreas cancer plasma and human prediagnostic plasma and, for TNC, in diagnostic plasma samples. M value plots for TNC and ERBB2 show elevated plasma levels in human prediagnostic (A) and mouse KPC plasma (B). TNC is also elevated in KPC tumor tissue (B) and diagnostic human plasma (C). Normalized M values (red/green ratios) for case and control samples are plotted along with the mean and SDs for each dataset. CA19-9 levels (U/mL) in prediagnostic (A) and diagnostic human samples (C) were also measured. Paired two-tailed t tests were used to determine statistical significance for human prediagnostic plasma and unpaired two-tailed t tests for mouse plasma and tissue and human diagnostic plasma datasets. All statistical analyses were conducted in GraphPad Prism 5.0; Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001.
previously reported in the plasma: ERBB2, KRT16, ESR1 (2 antibodies were in the top list), STAT3 (pY705), CLU, SERPINH1, TNC, and PKM (a third antibody to ESR1 showed increased levels with P < 0.06, not shown).
Cross-species biomarker identification
Plotting the M values (the normalized red/green ratio) of case and control samples for both prediagnostic human and preinvasive and invasive KPC plasma shows elevated levels of TNC and ERBB2 upregulated across species in cases versus controls with statistical significance ( Fig. 2A and B) . Increased tissue Erbb2 expression has been demonstrated previously by IHC in preinvasive and invasive PDA in KPC mice (12), corroborating our findings here. To determine whether tissues also expressed increased TNC, we interrogated tissue lysates from KPC mice at 2-and 4-months of age, representing preinvasive and preclinical invasive stages of disease, respectively. Array analyses of these tissue lysates showed increased TNC as represented by the M value plots of cases and controls (Fig. 2B) . We also performed IHC on tissues, revealing that TNC levels increased with progression from PanIN to invasive PDA (Fig.  3) . Of note, stromal deposition of TNC was seen in regions surrounding even the earliest PanIN-1 lesions (Fig. 3A) and increased along the PanIN-to-PDA progression scheme ( Fig. 3B and C). We did not observe appreciable increases in TNC in an experimental mouse model of chronic pancreatitis ( Fig. 3D and  H) , although others have reported modestly elevated levels in this setting (22) . Thus, the finding of elevated plasma ERBB2 and TNC identified through cross-species array analyses is further supported by corresponding increases in pancreatic tissues with preinvasive and invasive disease.
ESR1, ERBB2, and TNC as a marker panel for early diagnosis of pancreas cancer
An ROC curve (17) for prediagnostic samples was calculated for the 3-marker panel of ERBB2, ESR1 (both of two significant antibodies were included) and TNC, yielding an AUC ¼ 0.68 [95% confidence interval (CI), 0.58-0.77], with approximately 30% sensitivity at 90% specificity (Fig. 4) . Examination of time from blood draw to death in 1-year increments did not show any significant differences between the time points (see Supplementary Fig. S1 ). CA19-9 alone in these prediagnostic samples ( Fig.  2A) had an AUC ¼ 0.60 (95% CI, 0.52-0.69). When CA19-9 levels were included with TNC, ERBB2, and ESR1, the AUC did not increase significantly (0.71; 95% CI, 0.62-0.80; Fig. 4) .
Confirmation of ESR1, ERBB2, and TNC in diagnostic PDA plasma
We next interrogated the plasma proteome of diagnostic plasma samples collected through the CATPAC (see Table 1 for patient demographics, including age, stage and diagnosis, and smoking status). Twenty-four diagnostic plasma samples (13 from patients with resectable disease) and 24 control samples were interrogated on the array. Linear regression yielded 243 statistically significant (P < 0.05) candidates with 133 candidates increased in case versus control plasma (not shown). When evaluating the 23 upregulated markers identified from the WHI samples and, more specifically, TNC, ERBB2, and ESR1, in the CATPAC dataset, TNC was again increased with statistical significance (OR, 1.86; P ¼ 0.004); and ERBB2 (OR, 1.77; P ¼ 0.11) and ESR1 (OR, 1.62; P ¼ 0.055) each NOTE: Patient characteristics of cohort plasma from the WHI observational study and the CATPAC diagnostic plasma samples used in our antibody microarray analysis. WHI cases and controls were matched on an extensive list of criteria (see Materials and Methods) including age, ethnicity, smoking status, HRT status and BMI. Stage at diagnosis was determined using the T, N, and M classification system for pancreas cancer. 
Discussion
We applied a cross-species approach to discover and preliminarily validate plasma markers of PDA, using a high-density, pancreas cancer-tailored array platform. Most markers discovered from samples collected at diagnosis understandably do not perform well in prediagnostic samples (23) . Working from the other direction, we reasoned that array interrogation of plasma collected from the KPC mouse model at preinvasive and focally invasive stages of disease might serve as a useful starting point for initial discovery of markers of resectable disease. Proteins common to both murine and prediagnostic human plasma samples may represent true early detection markers for disease stages before the development of clinical symptoms. Such markers could potentially be used to more accurately diagnose early stages of pancreas cancer. PanIN have been identified in pancreata up to 10 years before the development of invasive PDA (24) and elevated blood glucose levels have been observed up to 5 years before the clinical diagnosis of PDA (25) . The fact that discernible changes in physiology become manifest years before diagnosis suggests, in principle, that clinically relevant plasma markers indicative of incipient PDA may exist and can be identified. Array interrogation of prediagnostic plasma from the WHI observational study mirrors the challenges of screening asymptomatic individuals. From this set of 87 prediagnostic plasma samples, we identified 23 proteins upregulated in case versus control plasma, 15 of which have been previously implicated in clinically diagnosed PDA.
Comparing the list of plasma membrane and secreted proteins identified in the murine discovery array experiments with the human plasma proteins previously implicated with pancreatic neoplasms revealed that TNC and ERBB2 were common to both. Elevated ERBB2 levels have been reported in PanIN and PDA in the KPC mouse model (12) , and increasing levels also correlate with progression from PanIN to invasive PDA in humans (22, 26) . Corresponding increases in serum ERBB2 levels have been reported and correlate with metastatic capability and survival (27) . That the majority of PDA cases overexpress ERBB2, whereas it is uniformly absent from normal ductal epithelium, makes it even more appealing as part of a candidate early detection marker panel.
We observed increasing levels of TNC with disease progression in KPC mice in both plasma and tissue and also found elevated levels of TNC in diagnostic human plasma samples, corroborating similar observations in human PDA (Supplementary Table S3 ; ref. 22) . A previously reported 3-marker panel of TNC, TFPI, and CA19-9 differentiated diagnostic PDA plasma samples from healthy controls with an AUC of 0.99 and 100% specificity at 90% sensitivity (28) . We also observed increased levels in diagnostic plasma of ESR1 and ERBB2 that trended toward significance. ESR1 expression has also been reported in invasive PDA (29) , and estrogen receptor positivity is a defining characteristic of stromal cells surrounding mucinous cystic neoplasms, which occur predominantly in women (30, 31) . Using ERBB2, ESR1, and TNC as a 3-marker panel yielded an AUC for prediagnostic plasma samples of 0.68, and an AUC of 0.86 for diagnostic samples. The AUCs increased to 0.71 and 0.97, respectively, when measured CA19-9 values were included. The 3-marker panel is superior to CA19-9 alone and could be of particular value in patients that are Lewis negative and cannot express CA19-9.
The studies reported here were conducted on plasma drawn up to 4 years before patient diagnosis, establishing proof-of-principle that a blood-based assay can identify PDA significantly earlier than current clinical modalities and before the onset of symptoms. An AUC approaching 0.7 for predicting incipient PDA that improves to 0.86 (or 0.97 with CA19-9 added) at diagnosis indicates that these markers could potentially help detect disease sufficiently early to be clinically meaningful. Moreover, the further improvement in the performance of the 3-marker panel in diagnostic versus prediagnostic samples suggests that these proteins increase with PDA progression. Our study underscores the difficulty of screening for pancreas cancer in asymptomatic individuals, and it must be acknowledged that the performance of this panel is still insufficient for screening in a general population, given the low incidence of the disease.
Further analyses of this 3-marker panel may be warranted initially in high-risk cohorts. A variety of at-risk individuals are currently being monitored in pancreas cancer registries, including patients with hereditary pancreatitis, those with two or more firstdegree relatives with PDA, and those with defined heritable syndromes such as Peutz-Jeghers intestinal polyposis (32) . The panel of ERBB2, ESR1, and TNC could also be examined retrospectively with imaging studies, which have high diagnostic potential, but are unable to detect microscopic precursor (PanIN) ductal lesions (33) . Should imaging modalities identify suspected lesions that are subsequently confirmed at surgery, plasma levels of these markers could be correlated with tumor histology, disease stage, disease latency, and survival.
The challenges for pancreas cancer biomarker discovery, validation, and implementation are significant. We propose that iterative cross-species analyses such as described here can foster the discovery, assessment, and contextualization of early detection markers, with the ultimate goal of use in general screening.
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